A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant enterococcus faecalis

Journal of Infectious Diseases

Volumn 211, Issue 8, 2015, Pages 1317-1325

  Reyes, Jinnethe ^a,f   Panesso, Diana ^a,f   Tran, Truc T ^a,b   Mishra, Nagendra N ^d,e   Cruz, Melissa R ^a   Munita, Jose M ^a,g   Singh, Kavindra V ^a   Yeaman, Michael R ^d,e   Murray, Barbara E ^a   Shamoo, Yousif ^c   Garsin, Danielle ^a   Bayer, Arnold S ^d,e   Arias, Cesar A ^a,f  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c RICE UNIVERSITY   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSIDAD EL BOSQUE   (Colombia)

^g UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

antimicrobial peptides; daptomycin; E. faecalis; LiaFSR

Indexed keywords

BETA DEFENSIN 3; CARDIOLIPIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DAPTOMYCIN; FRIULIMICIN; GALLIDERMIN; MERSACIDIN; NISIN; POLYPEPTIDE ANTIBIOTIC AGENT; RP 1; TELAVANCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GENE; CAENORHABDITIS ELEGANS; CELL MEMBRANE; CONTROLLED STUDY; DRUG TARGETING; ENTEROCOCCUS FAECALIS; GENE DELETION; IN VIVO STUDY; LIAR GENE; LIPID MEMBRANE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; GENETICS; GRAM-POSITIVE BACTERIAL INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; CAENORHABDITIS ELEGANS; CARDIOLIPINS; CELL MEMBRANE; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; SEQUENCE DELETION;

EID: 84926668434     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu602     Document Type: Article

References (49)

1. World Health Organization (WHO). Antimicrobial resistance global report on surveillance 2014. Geneva, Switzerland: WHO, 2014.
2. Centers for Diseases Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: Department of Health and Human Services, CDC, 2013.
3. Zhang T, Muraih JK, Tishbi N, et al. Cardiolipin prevents membrane translocation and permeabilization by daptomycin. J Biol Chem 2014; 289:11584-91.
4. Muraih JK, Pearson A, Silverman J, Palmer M. Oligomerization of dap-tomycin on membranes. Biochim Biophys Acta 2011; 1808:1154-60.
5. Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 2013; 1277:139-58.
6. Pogliano J, Pogliano N, Silverman JA. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 2012; 194:4494-504.
7. Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo dap-tomycin resistance in enterococci. N Engl J Med 2011; 365:892-900.
8. Munita JM, Panesso D, Diaz L, et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting dap-tomycin breakpoints. Antimicrob Agents Chemother 2012; 56:4354-9.
9. Munita JM, Tran TT, Diaz L, et al. A liaF codon deletion abolishes dap-tomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 2013; 57:2831-3.
10. Tran TT, Panesso D, Mishra NN, et al. Daptomycin resistant Enterococ-cus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio 2013; 4:e00281-13.
11. Miller C, Kong J, Tran TT, Arias CA, Saxer G, Shamoo Y. Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance [published correction appears in Antimicrob Agents Chemo-ther 2014; 58:631]. Antimicrob Agents Chemother 2013; 57:5373-83.
12. Jordan S, Junker A, Helmann JD, Mascher T. Regulation of LiaRS-dependent gene expression in Bacillus subtilis: identification of inhibitor proteins, regulator binding sites, and target genes of a conserved cell envelope stress-sensing two-component system. J Bacteriol 2006; 188:5153-66.
13. Suntharalingam P, Senadheera MD, Mair RW, Lévesque CM, Cvitkovitch DG. The LiaFSR system regulates the cell envelope stress response in Streptococcus mutans. J Bacteriol 2009; 191:2973-84.
14. Eldholm V, Gutt B, Johnsborg O, et al. The pneumococcal cell envelope stress-sensing system LiaFSR is activated by murein hydrolases and lipid II-interacting antibiotics. J Bacteriol 2010; 192:1761-73.
15. Mehta S, Cuirolo AX, Plata KB, et al. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to dapto-mycin in vivo selected clinical strains of methicillin-resistant Staphylo-coccus aureus. Antimicrob Agents Chemother 2012; 56:92-102.
16. Klinzing DC, Ishmael N, Dunning-Hotopp JC, et al. The two-component response regulator LiaR regulates cell wall stress responses, pili expression and virulence in group B Streptococcus. Microbiology 2013; 159:1521-34.
17. Boyle-Vavra S, Yin S, Jo DS, Montgomery CP, Daum RS. VraT/YvqF is required for methicillin resistance and activation of the VraSR regulon in Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57: 83-95.
18. Wolf D, Kalamorz F, Wecke T, et al. In-depth profiling of the LiaR response of Bacillus subtilis. J Bacteriol 2010; 192:4680-93.
19. Hachmann AB, Angert ER, Helmann JD. Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin. Antimicrob Agents Chemother 2009; 53:1598-609.
20. Kesel S, Mader A, Höfler C, Mascher T, Leisner MS. Immediate and heterogeneous response of the LiaFSR two-component system of Bacillus subtilis to the peptide antibiotic bacitracin. PLoS One 2013; 8:e53457.
21. Bourgogne A, Garsin DA, Qin X, et al. Large scale variation in Entero-coccus faecalis illustrated by the genome analysis of strain OG1RF. Genome Biol 2008; 9:R110.
22. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to dap-tomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005; 41:565-6.
23. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement 2013. CLSI document MS100-S23. CLSI: Wayne, PA, 2013.
24. Pfaller MA, Mendes RE, Sader HS, Jones RN. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother 2010; 65:2396-404.
25. Kristich CJ, Chandler JR, Dunny GM. Development of a host-genotype-independent counterselectable marker and a high-frequency conjuga-tive delivery system and their use in genetic analysis of Enterococcus faecalis. Plasmid 2007; 57:131-44.
26. Tran TT, Panesso D, Gao H, et al. Whole-genome analysis of a dapto-mycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 2012; 57:261-8.
27. Panesso D, Montealegre MC, Rincón S, et al. The hylEfm gene in pHy-lEfm of Enterococcus faecium is not required in pathogenesis of murine peritonitis. BMC microbiol 2011; 11:20.
28. Arthur M, Depardieu F, Snaith HA, Reynolds PE, Courvalin P. Contribution of VanY D, D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Anti-microb Agents Chemother 1994; 38:1899-903.
29. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52:269-78.
30. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Anti-microb Agents Chemother 2005; 49:3114-21.
31. Yeaman MR, Puentes SM, Norman DC, Bayer AS. Partial characterization and staphylocidal activity of thrombin-induced platelet microbici-dal protein. Infect Immun 1992; 60:1202-9.
32. Garsin DA, Sifri CD, Mylonakis E, et al. A simple model host for identifying Gram-positive virulence factors. Proc Natl Acad Sci USA 2001; 98:10892-7.
33. Mileykovskaya E, Dowhan W, Birke RL, Zheng D, Lutterodt L, Haines TH. Cardiolipin binds nonyl acridine orange by aggregating the dye at exposed hydrophobic domains on bilayer surfaces. FEBS Lett 2001; 507:187-90.
34. Petit JM, Maftah A, Ratinaud MH, Julien R. 10N-nonyl acridine orange interacts with cardiolipin and allows the quantification of this phospho-lipid in isolated mitochondria. Eur J Biochem 1992; 209:267-73.
35. Yount NY, Yeaman MR. Peptide antimicrobials: cell wall as a bacterial target. Ann N Y Acad Sci 2013; 1277:127-38.
36. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012; 280:2-35.
37. Jarczak J, Kosciuczuk EM, Lisowski P, et al. Defensins: natural component of human innate immunity. Hum Immunol 2013; 74:1069-79.
38. Islam MR, Nagao J, Zendo T, Sonomato K. Antimicrobial mechanism of lantibiotics. Biochem Soc Trans 2012; 40:1528-33.
39. Kilelee E, Pokorny A, Yeaman MR, Bayer AS. Lysyl-phosphatidylglycer-ol attenuates membrane perturbation rather than surface association of the cationic antimicrobial peptide 6W-RP-1 in a model membrane system: implications for daptomycin resistance. Antimicrob Agents Chemother 2010; 54:4476-9.
40. Schneider T, Gries K, Josten M, et al. The lipopeptide antibiotic Friuli-micin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob Agents Chemother 2009; 53: 1610-8.
41. Yount NY, Cohen SE, Kupferwasser D, et al. Context mediates antimicrobial efficacy of kinocidin congener peptide RP-1. PLoS One 2011; 6: e26727.
42. Sifri CD, Mylonakis E, Singh KV, et al. Virulence effect of Enterococcus faecalis protease genes and the quorum-sensing locusfsr in Caenorhab-ditis elegans and mice. Infect Immun 2002; 70:5647-50.
43. Gao P, Pinkston KL, Bourgogne A, et al. Library screen identifies Enterococcus faecalis CcpA, the catabolite control protein A, as an effector of Ace, a collagen adhesion protein linked to virulence. J Bacteriol 2013; 195:4761-8.
44. Balla KM, Troemel ER. Caenorhabditis elegans as a model for intracellular pathogen infection. Cell Microbiol 2013; 15:1313-22.
45. Simonsen KT, Gallego SF, Færgeman NJ, Kallipolitis BHK. Strength in numbers: "Omics" studies of C. elegansinnate immunity. Virulence 2012; 3:477-84.
46. Wong D, Bazopoulou D, Pujol N, Tavernarakis N, Ewbank JJ. Genome-wide investigation reveals pathogen-specific and shared signatures in the response of Caenorhabditis elegans to infection. Genome Biol 2007; 8:R194.
47. Tremblay YD, Lo H, Li YH, Halperin SA, Lee SF. Expression of the Streptococcus mutans essential two-component regulatory system VicRK is pH and growth-phase dependent and controlled by the LiaFSR three-component regulatory system. Microbiology 2009; 155:2856-65.
48. Bergholz TM, Tang S, Wiedmann M, Boor KJ. Nisin resistance of Listeria monocytogenes is increased by exposure to salt stress and is mediated via LiaR. Appl Environ Microbiol 2013; 79:5682-8.
49. Mileykovskaya E, Dowhan W. Cardiolipin membrane domains in pro-karyotes and eukaryotes. Biochim Biophys Acta 2009; 1788:2084-91.